The stock has a 36-month beta value of 2.01. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for PACB is 259.66M, and at present, short sellers hold a 18.69% of that float. On May 07, 2024, the average trading volume of PACB was 10.11M shares.
PACB) stock’s latest price update
Pacific Biosciences of California Inc (NASDAQ: PACB) has seen a rise in its stock price by 8.74 in relation to its previous close of 1.83. However, the company has experienced a 24.37% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-02 that Pacific Biosciences (PACB) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
PACB’s Market Performance
PACB’s stock has risen by 24.37% in the past week, with a monthly drop of -40.60% and a quarterly drop of -69.10%. The volatility ratio for the week is 14.03% while the volatility levels for the last 30 days are 14.02% for Pacific Biosciences of California Inc The simple moving average for the past 20 days is -3.76% for PACB’s stock, with a -73.30% simple moving average for the past 200 days.
Analysts’ Opinion of PACB
Goldman, on the other hand, stated in their research note that they expect to see PACB reach a price target of $2.50, previously predicting the price at $7. The rating they have provided for PACB stocks is “Neutral” according to the report published on April 18th, 2024.
Stephens gave a rating of “Overweight” to PACB, setting the target price at $11 in the report published on December 14th of the previous year.
PACB Trading at -40.32% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.32% of loss for the given period.
Volatility was left at 14.02%, however, over the last 30 days, the volatility rate increased by 14.03%, as shares sank -42.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -61.06% lower at present.
During the last 5 trading sessions, PACB rose by +24.37%, which changed the moving average for the period of 200-days by -84.91% in comparison to the 20-day moving average, which settled at $1.9948. In addition, Pacific Biosciences of California Inc saw -79.71% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PACB starting from Meline David W, who purchase 40,000 shares at the price of $4.40 back on Mar 06 ’24. After this action, Meline David W now owns 40,000 shares of Pacific Biosciences of California Inc, valued at $176,160 using the latest closing price.
HENRY CHRISTIAN O, the of Pacific Biosciences of California Inc, sale 14,177 shares at $4.87 during a trade that took place back on Mar 04 ’24, which means that HENRY CHRISTIAN O is holding 2,596,670 shares at $69,056 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -1.66 for the present operating margin
- 0.27 for the gross margin
The net margin for Pacific Biosciences of California Inc stands at -1.5. The total capital return value is set at -0.2. Equity return is now at value -48.53, with -17.46 for asset returns.
Based on Pacific Biosciences of California Inc (PACB), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at -0.29. The debt to equity ratio resting at 1.29. The interest coverage ratio of the stock is -23.24.
Currently, EBITDA for the company is -277.67 million with net debt to EBITDA at -2.64. When we switch over and look at the enterprise to sales, we see a ratio of 6.42. The receivables turnover for the company is 5.48for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.81.
Conclusion
To sum up, Pacific Biosciences of California Inc (PACB) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
